Human papilloma virus and lupus: The virus, the vaccine and the disease

Current Opinion in Rheumatology

Volumn 29, Issue 4, 2017, Pages 331-342

  Segal, Yahel ^a   Calabrò, Michele ^b   Kanduc, Darja ^c   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Department of Emergency and Organ Transplantation ^*  (Israel)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

autoimmunity; cross reactivity; human papilloma virus; molecular homology; systemic lupus erythematosus

Indexed keywords

PEPTIDE VACCINE; WART VIRUS VACCINE; AUTOANTIGEN; VIRAL PROTEIN;

AUTOIMMUNITY; CROSS REACTION; HUMAN; NONHUMAN; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROEPIDEMIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VACCINATION; WART VIRUS; IMMUNOLOGY; PAPILLOMAVIRIDAE; RISK FACTOR;

AUTOANTIGENS; CROSS REACTIONS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; VIRAL PROTEINS;

EID: 85017246379     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000398     Document Type: Review

References (132)

1. Santana IU, Gomes A, do N, et al. Systemic lupus erythematosus, human papillomavirus infection, cervical premalignant and malignant lesions: a systematic review. Clin Rheumatol 2011; 30: 665-672.
2. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus 2001; 10: 394-400.
3. Tommasino M. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 2014; 26: 13-21.
4. Iversen O-E, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 2016; 316: 2411-2421.
5. Paavonen J, Naud P, Salmerön J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet Lond Engl 2009; 374: 301-314.
6. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943.
7. Barzilai O, Sherer Y, Ram M, et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y Acad Sci 2007; 1108: 567-577.
8. Agmon-Levin N, Rose NR, Shoenfeld Y. Infection and autoimmunity. 2nd ed. United Kingdom: Elsevier BV; 2015.
9. Segal Y, Dahan S, Calabrò M, et al. HPV and systemic lupus erythematosus: a mosaic of potential crossreactions. Immunol Res 2017. [Epub ahead of print]
10. Rowley D, Jenkin CR. Antigenic cross-reaction between host and parasite as a possible cause of pathogenicity. Nature 1962; 193: 151-154.
11. Oldstone MB. Molecular mimicry and immune-mediated diseases. FASEB J Off Publ Fed Am Soc Exp Biol 1998; 12: 1255-1265.
12. Kanduc D, Stufano A, Lucchese G, Kusalik A. Massive peptide sharing between viral and human proteomes. Peptides 2008; 29: 1755-1766.
13. Kanduc D. The self/nonself issue. Self Nonself 2010; 1: 255-258.
14. Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. Lupus 2009; 18: 1181-1185.
15. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010; 19: 1485-1491.
16. Lyrio LDC, Grassi MFR, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 2013; 33: 335-340.
17. Raposo A, Tani C, Costa J, Mosca M. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review. Acta Reumatol Port 2016; 41: 184-190.
18. Joura EA, Giuliano AR, Iversen O-E, et al. A 9-Valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711-723.
19. Lundström E, Gustafsson JT, Jö nsen A, et al. HLA-DRB104/13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1018-1025.
20. Bettencourt A, Carvalho C, Leal B, et al. The protective role of HLADRB1 -13 in autoimmune diseases. J Immunol Res [Internet] 2015; 2015: 948723.
21. Amici A, Emanuelli M, Raffaelli N, et al. Human erythrocyte pyrimidine 5-nucleotidase, PN-I, is identical to p36, a protein associated to lupus inclusion formation in response to alpha-interferon. Blood 2000; 96: 1596-1598.
22. Karpouzas GA. Hematologic and lymphoid abnormalities in SLE [Internet]. Philadelphia, PA: Lippincott Williams Wilkins; 2007.
23. Kozyrev SV, Abelson A-K, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 211-216.
24. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358: 900-909.
25. Yang Y, Chung EK, WuYL, et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 2007; 80: 1037-1054.
26. Wu Y-L, Higgins GC, Rennebohm RM, et al. Three distinct profiles of serum complement C4 proteins in pediatric systemic lupus erythematosus (SLE) patients: tight associations of complement C4 and C3 protein levels in SLE but not in healthy subjects. Adv Exp Med Biol 2006; 586: 227-247.
27. Wilson WA, Perez MC. Complete C4B deficiency in black Americans with systemic lupus erythematosus. J Rheumatol 1988; 15: 1855-1858.
28. Tsokos G, Gordon C, Smolen JS. Systemic lupus erythematosus: a companion to rheumatology. Philadelphia, PA: Elsevier Health Sciences; 2007; 602 p. Vol. pp. 46-54, 183-193, 329-335.
29. Wetsel RA, Kulics J, Lokki ML, et al. Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189-> Phe; Gly444-> Arg) cause impaired C2 secretion. J Biol Chem 1996; 271: 5824-5831.
30. Singer L, Whitehead WT, Akama H, et al. Inherited human complement C3 deficiency. An amino acid substitution in the beta-chain (ASP549 to ASN) impairs C3 secretion. J Biol Chem 1994; 269: 28494-28499.
31. Racila DM, Sontheimer CJ, Sheffield A, et al. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 2003; 12: 124-132.
32. Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3596-3604.
33. Arora V, Grover R, Kumar A, et al. Relationship of leukocyte CR1 transcript and protein with the pathophysiology and prognosis of systemic lupus erythematosus: a follow-up study. Lupus 2011; 20: 1010-1018.
34. Verma J, Arora V, Marwaha V, et al. Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus. Lupus 2005; 14: 273-279.
35. Wu H, Boackle SA, Hanvivadhanakul P, et al. Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus. Proc Natl Acad Sci U S A 2007; 104: 3961-3966.
36. Barreto M, Santos E, Ferreira R, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet EJHG 2004; 12: 620-626.
37. Lee YH, Harley JB, Nath SK. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum Genet 2005; 116: 361-367.
38. Al-Mayouf SM, Sunker A, Abdwani R, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet 2011; 43: 1186-1188.
39. Xiang N, Li X-P, Li X-M, et al. Expression of Ets-1 and FOXP3 mRNA in CD4()CD25 () T regulatory cells from patients with systemic lupus erythematosus. Clin Exp Med 2014; 14: 375-381.
40. Huang X, Shen N, Bao C, et al. Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther 2008; 10: R91.
41. Jacob CO, Reiff A, Armstrong DL, et al. Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum 2007; 56: 4164-4173.
42. Lee YH, Bae S-C. Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: an update meta-analysis. Rheumatol Int 2015; 35: 815-823.
43. Nath SK, Han S, Kim-Howard X, et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008; 40: 152-154.
44. Hou Y-F, Zhang Y-C, Jiao Y-L, et al. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus 2010; 19: 20-26.
45. Pellett F, Siannis F, Vukin I, et al. KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007; 69 (Suppl 1): 106-108.
46. Toloza S, Pellett F, Chandran V, et al. Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. Lupus 2008; 17: 793-798.
47. Bai Y, Zhang Y, Yang Q, et al. The aberrant expression of stimulatory and inhibitory killer immunoglobulin-like receptors in NK-and NKT-cells contributes to lupus. Clin Lab 2014; 60: 717-727.
48. Hou Y, Zhang C, Xu D, Sun H. Association of killer cell immunoglobulin-like receptor and human leucocyte antigen-Cw gene combinations with systemic lupus erythematosus. Clin Exp Immunol 2015; 180: 250-254.
49. Chen J, WuM, Wang J, Li X. Immunoregulation of NKT cells in systemic lupus erythematosus. J Immunol Res 2015; 2015: 206731.
50. Poggi A, Zocchi MR. NK cell autoreactivity and autoimmune diseases. Front Immunol 2014; 5: 27.
51. Spada R, Rojas JM, Barber DF. Recent findings on the role of natural killer cells in the pathogenesis of systemic lupus erythematosus. J Leukoc Biol 2015; 98: 479-487.
52. Belot A, Kasher PR, Trotter EW, et al. Protein kinase cd deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum 2013; 65: 2161-2171.
53. Chambers JC, Kenan D, Martin BJ, Keene JD. Genomic structure and amino acid sequence domains of the human La autoantigen. J Biol Chem 1988; 263: 18043-18051.
54. Valavanis C, Wang Z, Sun D, et al. Acheron, a novel member of the Lupus Antigen family, is induced during the programmed cell death of skeletal muscles in the moth Manduca sexta. Gene 2007; 393: 101-109.
55. Li N, Nakamura K, Jiang Y, et al. Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus. Hum Mol Genet 2004; 13: 171-179.
56. McCurdy DK, Tai LQ, Nguyen J, et al. MAGE Xp-2: a member of the MAGE gene family isolated from an expression library using systemic lupus erythematosus sera. Mol Genet Metab 1998; 63: 3-13.
57. Sawalha AH, Webb R, Han S, et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One 2008; 3: e1727.
58. Webb R, Wren JD, Jeffries M, et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1076-1084.
59. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356: 1216-1225.
60. Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12: 392-398.
61. Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505-2514.
62. Kozora E, West SG, Maier SF, et al. Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes. J Neurol Sci 2010; 295: 87-91.
63. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2515-2522.
64. Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 1210-1213.
65. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33: 1553-1558.
66. Hirohata S, Arinuma Y, Yanagida T, Yoshio T. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther 2014; 16: R77.
67. Ogawa E, Nagai T, Sakuma Y, et al. Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus. Mod Rheumatol 2016; 26: 377-383.
68. Steup-Beekman G, Steens S, van Buchem M, Huizinga T. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16: 329-334.
69. Schneebaum AB, Singleton JD, West SG, et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 1991; 90: 54-62.
70. Lauvsnes MB, Beyer MK, Kvaløy JT, et al. Association of hippocampal atrophy with cerebrospinal fluid antibodies against the NR2 subtype of the N-methyl-D-aspartate receptor in patients with systemic lupus erythematosus and patients with primary Sjö gren's syndrome. Arthritis Rheumatol Hoboken NJ 2014; 66: 3387-3394.
71. Banham-Hall E, Clatworthy MR, Okkenhaug K. The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 2012; 6: 245-258.
72. Namjou B, Kim-Howard X, Sun C, et al. PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes. PLoS One 2013; 8: e69404.
73. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75: 504-507.
74. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36: 337-338.
75. Lee YH, Choi SJ, Ji JD, Song GG. Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis. Inflamm Res Off J Eur Histamine Res Soc Al 2012; 61: 949-954.
76. Segovia-Miranda F, Serrano F, Dyrda A, et al. Pathogenicity of lupus antiribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model. Arthritis Rheumatol Hoboken NJ 2015; 67: 1598-1610.
77. Massardo L, Bravo-Zehnder M, Calderön J, et al. Anti-N-methyl-D-aspartate receptor and antiribosomal-P autoantibodies contribute to cognitive dysfunction in systemic lupus erythematosus. Lupus 2015; 24: 558-568.
78. Ramantani G, Kohlhase J, Hertzberg C, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutiè res syndrome. Arthritis Rheum 2010; 62: 1469-1477.
79. Së raphin B. Sm and Sm-like proteins belong to a large family: identification of proteins of the U6 as well as the U1, U2, U4 and U5 snRNPs. EMBO J 1995; 14: 2089-2098.
80. Huntriss JD, Latchman DS, Williams DG. Lupus autoantibodies discriminate between the highly homologous Sm polypeptides B/B0 and SmN by binding an epitope restricted to B/B0. Clin Exp Immunol 1993; 92: 263-267.
81. Santoro P, De Andrea M, Migliaretti G, et al. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases. J Rheumatol 2002; 29: 90-93.
82. Kariuki SN, Kirou KA, MacDermott EJ, et al. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol Baltim Md 19502009; 182: 34-38.
83. Cai L-Q, Wang Z-X, Lu W-S, et al. A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population. Mol Biol Rep 2010; 37: 389-394.
84. Gateva V, Sandling JK, Hom G, et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1228-1233.
85. Gehrke N, Mertens C, Zillinger T, et al. Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STINGdependent immune sensing. Immunity 2013; 39: 482-495.
86. Goes FS, HamshereML, Seifuddin F, et al. Genome-wide association ofmoodincongruent psychotic bipolar disorder. Transl Psychiatry 2012; 2: e180.
87. Kanduc D. Pentapeptides as minimal functional units in cell biology and immunology. Curr Protein Pept Sci 2013; 14: 111-120.
88. Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of molecular mimicry between human papillomavirus 16 E7 oncoprotein and human protein sequences. Immunol Cell Biol 2000; 78: 580-585.
89. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1130-1135.
90. Fragoso-Loyo H, Cabiedes J, Orozco-Narvä ez A, et al. Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One 2008; 3: e3347.
91. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 2014; 73: 1601-1606.
92. Lange K, Wasserman E, Slobody LB. The significance of serum complement levels for the diagnosis and prognosis of acute and subacute glomerulonephritis and lupus erythematosus disseminatus. Ann Intern Med 1960; 53: 636-646.
93. Park Y-W, Kee S-J, Cho Y-N, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1753-1763.
94. Ytterberg SR, Schnitzer TJ. Inhibition of natural killer cell activity by serum from patients with systemic lupus erythematosus: roles of disease activity and serum interferon. Ann Rheum Dis 1984; 43: 457-461.
95. Egan ML, Mendelsohn SL, Abo T, Balch CM. Natural killer cells in systemic lupus erythematosus. Arthritis Rheum 1983; 26: 623-629.
96. Green MRJ, Kennell ASM, Larche MJ, et al. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005; 141: 165-173.
97. Yabuhara A, Yang FC, Nakazawa T, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996; 23: 171-177.
98. Geiger TL, Sun JC. Development and maturation of natural killer cells. Curr Opin Immunol 2016; 39: 82-89.
99. Poli A, Kmiecik J, Domingues O, et al. NK cells in central nervous system disorders. J Immunol Baltim Md 19502013; 190: 5355-5362.
100. Hao J, Liu R, Piao W, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med 2010; 207: 1907-1921.
101. Gascon E, Vutskits L, Kiss JZ. Polysialic acid-neural cell adhesion molecule in brain plasticity: from synapses to integration of new neurons. Brain Res Rev 2007; 56: 101-118.
102. Conboy L, Tanrikut C, Zoladz PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009; 12: 329-341.
103. Nï Dhü ill CM, Fox GB, Pittock SJ, et al. Polysialylated neural cell adhesion molecule expression in the dentate gyrus of the human hippocampal formation from infancy to old age. J Neurosci Res 1999; 55: 99-106.
104. Migaud M, Batailler M, Segura S, et al. Emerging new sites for adult neurogenesis in the mammalian brain: a comparative study between the hypothalamus and the classical neurogenic zones. Eur J Neurosci 2010; 32: 2042-2052.
105. Quartu M, Serra MP, Boi M, et al. Polysialylated-neural cell adhesion molecule (PSA-NCAM) in the human trigeminal ganglion and brainstem at prenatal and adult ages. BMC Neurosci 2008; 9: 108.
106. Brennaman LH, Maness PF. NCAM in neuropsychiatric and neurodegenerative disorders. Adv Exp Med Biol 2010; 663: 299-317.
107. Tahmasian M, Rosenzweig I, Eickhoff SB, et al. Structural and functional neural adaptations in obstructive sleep apnea: an activation likelihood estimation meta-analysis. Neurosci Biobehav Rev 2016; 65: 142-156.
108. Chotinaiwattarakul W, O'Brien LM, Fan L, Chervin RD. Fatigue, tiredness, and lack of energy improve with treatment for OSA. J Clin Sleep Med 2009; 5: 222-227.
109. Wainwright SR, Galea LAM. The neural plasticity theory of depression: assessing the roles of adult neurogenesis and PSA-NCAM within the hippocampus. Neural Plast 2013; 2013: e805497.
110. Fasick V, Spengler RN, Samankan S, et al. The hippocampus and TNF: common links between chronic pain and depression. Neurosci Biobehav Rev 2015; 53: 139-159.
111. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006; 55: 628-635.
112. Taylor-Gjevre RM, Nair BV, Gjevre JA. Obstructive sleep apnoea in relation to rheumatic disease. Rheumatology 2013; 52: 15-21.
113. Abad VC, Sarinas PSA, Guilleminault C. Sleep and rheumatologic disorders. Sleep Med Rev 2008; 12: 211-228.
114. Iaboni A, Ibanez D, Gladman DD, et al. Fatigue in systemic lupus erythematosus: contributions of disordered sleep, sleepiness, and depression. J Rheumatol 2006; 33: 2453-2457.
115. Tsokos GC, Gordon C, Smolen JC, editors. Systemic lupus erythematosus: a companion to Rheumatology. Vol. 329-335. Philadelphia, PA: Mosby Elsevier; 2007.
116. Baker B, Eça Guimaraes L, Tomljenovic L, et al. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 2015; 14: 1387-1394.
117. Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 2014; 21: 135-139.
118. Brinth L, Theibel AC, Pors K, Mehlsen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J 2015; 62: A5064.
119. Bizjak M, BruckO, Praprotnik S, et al. Pancreatitis after human papillomavirus vaccination: a matter of molecular mimicry. Immunol Res 2016. [Epub ahead of print]
120. Das A, Chang D, Biankin AV, Merrett ND. Pancreatitis following human papillomavirus vaccination. Med J Aust 2008; 189: 178.
121. Little DT, Ward HRG. Adolescent premature ovarian insufficiency following human papillomavirus vaccination. J Investig Med High Impact Case Rep [Internet] 2014; 2: 2324709614556129.
122. Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/ inflammatory syndrome induced by adjuvants. Am J Reprod Immunol 2013; 70: 309-316.
123. Pellegrino P, Perrone V, Pozzi M, et al. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res 2015; 61: 90-96.
124. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013; 32: 1301-1307.
125. Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012; 21: 158-161.
126. Ito H, Noda K, Hirai K, et al. A case of systemic lupus erythematosus (SLE) following human papillomavirus (HPV) vaccination. Nihon Rinsho Meneki Gakkai Kaishi 2016; 39: 145-149.
127. Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res 2016. [Epub ahead of print]
128. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013; 11: 29.
129. Perricone C, Agmon-Levin N, Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med 2013; 11: 101.
130. Arango M-T, Perricone C, Kivity S, et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunol Res 2016. [Epub ahead of print]
131. Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 2015; 18: 17-28. 132.
132. Kanduc D, Shoenfeld Y. From HBV to HPV: designing vaccines for extensive and intensive vaccination campaigns worldwide. Autoimmun Rev 2016; 15: 1054-1061.